middle.news
How Prescient Therapeutics Is Advancing PTX-100 Amid Narrowing Losses
8:45pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
How Prescient Therapeutics Is Advancing PTX-100 Amid Narrowing Losses
8:45pm on Friday 29th of August, 2025 AEST
Key Points
Net loss improved 11.1% to $7.32 million for FY2025
PTX-100 advanced from Phase 1b to Phase 2a clinical trials targeting cutaneous T-cell lymphoma
FDA granted Fast Track and Orphan Drug designations for PTX-100
Research and development tax incentives increased to $4.36 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE